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Abstract
Background: There remains uncertainty regarding the appropriate therapeutic management of hip fracture
patients. The primary aim of our study was to examine whether large loading doses in addition to daily vitamin D
offered any advantage over a simple daily low-dose vitamin D regimen for increasing vitamin D levels.
Methods: In this randomized controlled study, patients over age 50 with an acute fragility hip fracture were
enrolled from two hospital sites in Ontario, Canada. Participants were randomized to one of three loading dose
groups: placebo; 50,000 IU vitamin D2; or 100,000 IU D2. Following a placebo/loading dose, all patients received a
daily tablet of 1,000 IU vitamin D3 for 90 days. Serum 25-hydroxy vitamin D (25-OHD) was measured at baseline,
discharge from acute care (approximately 4-weeks), and 3-months.
Results: Sixty-five patients were enrolled in the study (44% male). An immediate rise in 25-OHD occurred in the
100,000 group, however there were no significant differences in 25-OHD between the placebo, 50,000 and 100,000
loading dose groups after 4-weeks (69.3, 84.5, 75.6 nmol/L, p = 0.15) and 3-months (86.7, 84.2, 73.3 nmol/L, p =
0.09), respectively. At the end of the study, approximately 75% of the placebo and 50,000 groups had reached the
target therapeutic range (75 nmol/L), and 44% of the 100,000 group.
Conclusions: In correcting vitamin D insufficiency/deficiency in elderly patients with hip fracture, our findings
suggest that starting with a lower daily dose of Vitamin D3 achieved similar results as providing an additional large
loading dose of Vitamin D2. At the end of the study, all three groups were equally effective in attaining
improvement in 25-OHD levels. Given that a daily dose of 1,000 IU vitamin D3 (with or without a loading dose)
resulted in at least 25% of patients having suboptimal vitamin D status, patients with acute hip fracture may
benefit from a higher daily dose of vitamin D.
Trial registration: Clinical Trials # NCT00424619
Background
Vitamin D deficiency is a major risk factor for acceler-
ated bone loss and fracture [1]. Insufficient vitamin D
levels lead to reduced calcium absorption (particularly at
low-to-moderate calcium intakes), elevated serum para-
thyroid hormone, and increased rates of bone resorp-
tion, which over time may lead to bone fracture [2]. The
optimal level of serum 25-hydroxyvitamin D3 (25-OHD)
for bone health has been defined by a consensus panel
as 75 nmol/L [3]. This level has also been endorsed by
Osteoporosis Canada [4] and the International Osteo-
porosis Foundation [5].
There is evidence from a number of meta-analyses
that supplementation with at least 800 to 1,000 IU/day
vitamin D3 reduces fractures [6,7] and falls [8]. The
level of serum 25-OHD achieved is also an important
consideration. It has been demonstrated that falls and
fracture reductions are more consistently achieved when
serum 25-OHD levels are at least 60 nmol/L and 75
nmol/L, respectively [9-11].
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rent hip fracture or other fragility fractures [12] and
should be targeted for osteoporosis treatment (i.e.
bisphosphonate or other antiresorptive). Before hip frac-
ture patients are initiated on bisphosphonate therapy, an
important consideration is whether 25-OHD is at a
therapeutic level [13,14]. The majority of patients with
hip fracture have been found to have lower serum con-
centrations of 25-OHD than those without a fracture
[15-19].
There remains uncertainly regarding the appropriate
management of hip fracture patients in the acute frac-
ture period, particularly for patients who are severely
vitamin D deficient. Several studies have examined var-
ious vitamin D dosing strategies in patients with frac-
tures and/or elderly cohorts [20-24]. However, the focus
of previous studies was comparing the timing of dosing
(i.e., daily versus weekly versus monthly). Whether sup-
plementing patients with a large loading dose of vitamin
D2 in addition to daily vitamin D3 offers any advantage
over simply prescribing daily vitamin D3 is yet to be
determined. Thus, the primary aim of our study was to
compare change in 25-OHD levels after supplementa-
tion with daily vitamin D3 plus one of three loading dos-
ing regimens: 1) placebo bolus 2) 50,000 IU vitamin D2
3) 100,000 IU vitamin D2.
Methods
Participants
Between October 2007 and April 2009, consenting and
eligible patients over age 50 with an acute fragility hip
fracture (defined as femoral neck, trochanteric, subtro-
chanteric or subcapital) which was the result of a mini-
mal trauma accident, defined as a fall from standing
height or less, were enrolled from two large academic
hospital sites in Hamilton, Ontario, Canada. Patients
w e r en o te l i g i b l ei ft h e yh a dp e lvic fractures; pathologi-
cal fractures secondary to malignancy or intrinsic bone
disease (e.g. Paget’s disease); pre-existing bone abnorm-
ality; cancer in the past 10 years likely to metastasize to
bone; renal insufficiency (creatinine <30 mls/min); renal
stones in past 10 years; hypercalcemia (primary hyper-
parathyroidism; granulomatous diseases); hypocalcemia;
stroke within the last 3 months; or had taken hormone
replacement therapy, calcitonin, bisphosphonates, raloxi-
fen, or parathyroid hormone during the previous 24
months. Patients admitted from long-term care facil-
ities/nursing homes were also excluded.
Study Protocol
This was a parallel, double-blind, randomized controlled
study. The central in-patient pharmacy at McMaster
University Medical Centre coordinated the randomiza-
tion procedure and the distribution of study drugs.
Patients were randomized in blocks according to a com-
puter-generated randomization list. The medication
treatment group was concealed and all participants,
study coordinators, physicians, staff, and caregivers were
blinded to treatment group allocation. An overview of
the study was provided to potential participants by sur-
gical staff during routine examination (prior to or fol-
lowing hip fracture repair). Study coordinators followed-
up with patient enrolment and informed consent within
7 days pre or post-operatively.
Participants were randomized to one of three groups
which differed only by the oral bolus loading dose
received on day 1: placebo bolus, 50,000 IU vitamin D2,
or 100,000 IU vitamin D2. Following the one-time bolus
dose at baseline, patients in all groups received a daily
tablet of 1,000 IU vitamin D3 for 90 days. Vitamin D
bolus doses and tablets were dispensed by nursing staff
while in-hospital. Prior to discharge from hospital, study
coordinators provided participants with the remainder
of the 1,000 IU vitamin D3 tablets to be taken daily and
reviewed medication instructions. Additional daily vita-
min D3 (1,000 IU) pills were provided to participants if
their 3-month examination date was extended. Adher-
ence data for the inpatient period was provided by the
hospital pharmacist, and pill counts for the post-dis-
charge period were conduct e da tt h e3 - m o n t hc l i n i c
appointment by the study coordinators. Adherence was
defined as taking at least 80% of dispensed daily vitamin
D3 pills.
Vitamin D3 (cholecalciferol) is the molecule that is
synthesized in the skin in response to ultraviolet B light
exposure, while vitamin D2 (ergocalciferol) is derived
from irradiation of certain fungi. Both vitamin D2 and
vitamin D3 go through the stages of metabolism to cre-
ate the active form of vitamin D (1,25-dihydroxyvitamin
D), there is support that vitamin D2 may not be used as
efficiently as vitamin D3 in human physiology [25-27].
Study Measures
Laboratory
Serum 25-OHD was measured at baseline, discharge
from acute care at approximately 4-weeks, and at a fol-
low-up study visit at approximately 3-months. The mea-
surements may have been several days from the actual
4-week (mean = 26.3, standard deviation = 7.9) and 3-
month (mean = 99.0, standard deviation = 25.0) time
points but for simplicity they will be referred to as “4-
weeks” and “3m o n t h s ” throughout the paper. Baseline
blood samples were drawn in-hospital; additional veni-
punctures were performed prior to hospital discharge,
and at 3-months either in-hospital (for patients remain-
ing in acute care or rehabilitation) or at the out-patient
clinic visit. In addition to 25-OHD, serum calcium, para-
thyroid hormone (PTH), phosphate, albumin, alkaline
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at baseline.
Serum 25-OHD was analyzed with the DiaSorin, 25-
hydroxyvitamin D radioimmunoassay (Stillwater, Minne-
sota 55082-0285, U.S.A). The central laboratory analyzed
all 25-OHD tests with the exception of three patients
who had their final 25-OHD analyzed at alternate
laboratories for logistical reasons.
Clinical and demographic characteristics were
abstracted from the patient chart and obtained from a
patient or family interview for the purpose of describing
the population, and included living situation, fracture
history, family fracture history, ambulation status and
aids, number medications, co-morbidities and bispho-
sphonate use. The Charlson Index [28] was also calcu-
lated, based on 19 categories of co-morbidity (defined
by ICD-9-CM diagnosis and procedure codes) which are
weighted and tabulated into an overall co-morbidity
score. A higher score indicates greater disease burden.
Height and weight were abstracted from the patient’s
chart or measured at the 3-month clinic appointment.
This research was conducted in compliance with the
Helsinki declaration and ethics approval was received
from the Hamilton Health Sciences/McMaster Univer-
sity Faculty of Health Sciences Research Ethics Board.
T h eD a t aS a f e t yM o n i t o r i n gC o m m i t t e er e v i e w e da l l
adverse events.
Statistical Analysis
We reported the results in accordance with the Consoli-
dated Standards of Reporting Trials (CONSORT) cri-
teria [29]. Study data were entered and managed using
an ACCESS database (Microsoft Access 2000). Analyses
were performed with SPSS v.18 (SPSS Inc. Chicago, Illi-
nois) software package and SAS/Stat 9.1 (SAS Institute
Inc., Cary, North Carolina). All analyses were intention
to treat and included all available data (unless specified
in sub-group analyses). Descriptive data are presented as
means, standard deviation (SD), 95% confidence inter-
vals (95% CI) for continuous variables and as propor-
tions and percents for categorical data. Any outliers
above or below 3 standard deviations were checked
against original laboratory reports or chart documents.
Box plots were constructed to display the distributions
of 25-OHD values.
Baseline data were compared according to treatment
groups using one-way ANOVA; Post hoc pairwise com-
parisons were made using Bonferroni tests. Pearson’s
chi-square or Fisher’s exact tests were used to examine
categorical variables as appropriate.
ANCOVA analyses were used to compare differences
between groups on 25-OHD and functional measures,
adjusting for relevant variables. To account for variation
in when 25-OHD measures were collected, we
controlled for time to measure (i.e. days from bolus
administration to a 25-OHD measure). Multivariable
linear regression analysis was used to examine the per-
cent change in 25-OHD

post − pre
pre

∗ 100

between
baseline and follow-up measures, adjusting for time to
measure and baseline 25-OHD scores. The proportion
of patients reaching the target 25-OHD therapeutic level
(≥75 nmol/L) was also calculated and compared
between groups using chi-square analysis. The criterion
for statistical significance was set at alpha = 0.05.
Results
Of 626 patients screened for eligibility, 110 patients
were approached to participate in the study as displayed
in the CONSORT diagram (Figure 1). Of these, 45
denied consent and 65 were enrolled. Twenty-one of 65
(32%) patients were randomized to the placebo group,
and 22 of 65 (34%) patients each to the 50,000 IU vita-
min D2, and 100,000 IU vitamin D2 loading dose groups,
respectively. One participant randomized to the placebo
group was a screen failure (due to errantly receiving
post-operative orders for vitamin D) and no data was
collected on this patient.
Table 1 presents baseline clinical and laboratory
characteristics. The mean age of the 100,000 group was
significantly lower than the 50,000 group (p = 0.024).
This is likely explained by the greater proportion of
m e ni nt h e1 0 0 , 0 0 0g r o u pa st h em e ne n r o l l e di no u r
s t u d yt e n d e dt ob ey o u n g e rt h a nw o m e n( T a b l e1 ) .
Overall, 36 of 65 study participants (56%) were female.
Fourteen of 65 participants (21%) had a previous atrau-
matic fracture after the age of 40 years documented,
and 62% were ambulatory without aids prior to hip
fracture.
The box plots in Figure 2 illustrate the distribution of
serum 25-OHD values by treatment group at 4-weeks
and 3-months. There were no significant differences in
mean serum 25-OHD between groups at 4-weeks or
3-months (Table 2). By 4-weeks, 47-59% of patients had
reached the target therapeutic range (≥ 75 nmol/L). By
3-months, approximately 75% of the placebo and 50,000
groups had reached therapeutic range, and only 44% of
the 100,000 group, but the difference between groups in
the proportion of patients in the therapeutic range was
not statistically significant (Table 2).
In some cases, it was not possible to obtain a baseline
serum sample until after the bolus dose. However, this
limitation in timing allowed us to provide a descriptive
comparison of the immediate effects of the dosing regi-
mens. In this sub-group (n = 25) who had 25-OHD
measured 1-3 days after administration of the bolus
dose, there appeared to be an immediate rise in serum
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the difference was only significant for the 100,000 vita-
min D2 group compared with the placebo group (76.0
nmol/L versus 41.6 nmol/L, p = 0.03, Table 2).
In multiple linear regression analysis, controlling for
time (between bolus dose and 25-OHD measures) and
baseline 25-OHD, the percent change in 25-OHD was
not significantly different between the treatment arms at
4-weeks or 3-months (data not shown). The mean per-
cent change over 4-weeks was 43.3% (95% CI -0.29,
86.8), 100.3% (95% CI 59.3, 141.3), and 82.5% (95% CI
40.5, 124.5) for the placebo, 50,000 and 100,000 groups
Eligible based on screen (n=203)
Patient approached to participate in study, n=110
Not approached to participate (n=93) 
Post-operative standard orders filled, n=50
Severe cognitive illness (ie: dementia, delerium), n=8
Advised not to approach due to violent episodes, n=1
Unable to communicate (hearing impaired, language 
barrier), n=5
Not eligible fracture (ie:acetabular), n=11
Not from greater Hamilton area, n= 9
Post-operative life-threatening complications prevented 
contact with patient, n=6
Multiple comorbidities, unlikely to make 3-month 
timepoint, n=1
Death prior to approach, n=2
Randomized
(n= 65)
Allocated to Group A
Placebo (n=21)
Allocated to Group C
100, 0000 IU vitamin D2 (n= 22)
Completed 4-week/discharge 
assessment
(n= 17)
Completed 4-week/discharge 
assessment
(n= 18)
Completed follow-up assessment
n= 17
Completed follow-up assessment
n= 12
Screened for eligibility (n = 626 )
Ineligible based on screen (n= 423)
Age < 50 years old, n=10
Patient approached >1 week post-operative period, n=37
Bisphosphonate use <24 months ago, n=128
Calcitonin use <24 months ago, n=2
Hormone therapy use <24 months ago, n=5
Corticosteroid use >3 months at 2.5mg/day, n=5
Stroke <3 months ago, n=2
Metastatic cancer <5 years ago, n=27
Pathological fracture, n=17
Abnormally elevated Creatinine (weight unknown), n=6
Renal Insufficiency (CrCl<30 ml/min), n=26
Renal stones in <10 years ago, n=2
Patient admitted from a long-term care facility, n=128
Traumatic fracture, n=17
Male, n=11*
* exclusion criteria was modified to include males on 
October 11, 2007
Allocated to Group B
50, 000 IU vitamin D2 (n= 22)
Completed follow-up assessment
n = 18
Completed 4-week/discharge 
assessment
(n = 17)
Deny consent (n=45)
Not interested, n=26
Too overwhelmed, n=4
Cannot communicate well enough to provide consent, n=10
Does not like research, or unsure about safety, n=2
This study is a burden on care-providers, n=1
Patient does not want to take another pill, n=2
Figure 1 Patients Screened.
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percent change was 85.6% (95% CI 30.2, 141.0), 146.1%
(95% CI 83.8, 208.4), and 68.1% (95% CI 17.1, 119.1).
Safety
Five serious adverse events were reported: one in the
placebo group, two in the 50,000 group, and two in the
100,000 group. The serious adverse events were: 2
deaths, 1 fractured hip, 1 pulmonary edema and myo-
cardial infarction, 1 gangrenous left foot requiring
amputation. All were judged unrelated to the study
treatments by the Data Safety Monitoring Board.
Adherence
Of the 64 patients who received study medication while
in-hospital (until discharge to home/long-term care,
study withdrawal, or death), 54 participants (83%) were
adherent to daily 1,000 IU vitamin D3 (ie:, consumed at
least 80% of tablets). The mean (SD) in-hospital
compliance in the placebo, 50,000 IU and 100,000 IU
vitamin D2 groups were 97.1 (7.6%), 86.8 (16.2%) and
89.5 (12.5%), respectively (p = 0.033). Of 47 participants
who completed the final 25-OHD assessment, four par-
ticipants (8%) completed the study in-hospital and are
included in the above in-hospital adherence rate, and 13
(28%) did not bring their study pills to their clinic visit.
Of the remaining participants who attended the final
study visit, the mean (SD) at home compliance for those
in the placebo, 50,000 IU and 100,000 IU vitamin D2
groups were 84 (14.5%), 96.1 (9.3%) and 91.8 (15.2%),
respectively (p = 0.270).
Discussion
Our findings reveal that daily vitamin D3 with or with-
out a loading dose improves serum 25-OHD levels and
that this result was seen as early as 4-weeks. Further,
there were no significant differences in 25-OHD values
between loading dose groups after 4-weeks or 3-months
Table 1 Characteristics of study sample at baseline, according to treatment allocation
†
Placebo
n=2 1
50,000
n=2 2
100,000
n=2 2
Missing Cases (Placebo/50,000/100,000)
Age in years 78.5 (10.3) 82.9 (8.7) * 73.9(12.4) * 1/0/0
Male (SD) 77.9 (8.4) 77.9 (11.2) 69.5 (12.9)
Female (SD) 78.8 (11.5) 85.2 (6.4) 81.7 (6.6)
Gender 1/0/0
Male (%) 7 (35) 7 (32) 14 (64)
Female (%) 13 (65) 15 (68) 8 (36)
Height, cm 163.8 (11.4) 162.9 (10.1) 169.7 (12.6) 2/3/2
Male (SD) 174.8 (10.2) 173.5 (4.7) 175.0 (10.3)
Female (SD) 158.7 (7.9) 156.7 (6.3) 158.2 (7.3)
Weight, kg 70.6 (25.4) 64.8 (18.1) 72.1 (15.8) 2/2/2
Male (SD) 89.1 (30.3) 79.4 (12.7) 76.1 (10.8)
Female (SD) 62.1(18.4) 57.0 (15.8) 64.6 (21.4)
Prior Smoking (%) 9 (50) 7 (39) 11 (58) 3/4/3
Previous fracture documented (%) 3 (15) 5 (23) 6 (27) 1/0/0
Prior vitamin D use (%) 4 (20) 1 (4.5) 4 (18) 1/0/0
Prior calcium use (%) 5 (25) 2 (9) 4 (18) 1/0/0
Number of medications at admission (SD) 6.2 (4.6) 6.0 (3.8) 5.0 (4.4) 1/0/0
Charlson index (SD) 1.30 (1.13) 0.82 (1.18) 0.55 (0.80) 2/0/0
Ambulatory without aids prior to admission (%) 8 (44) 13 (72) 13 (68) 3/4/3
Total calcium, mmol/L (SD) 2.10 (0.14) 2.12 (0.11) 2.08 (0.14) 1/1/0
Hb, g/L (SD) 108.6 (15.2) 102.2 (14.3) 107.9 (17.4) 1/0/0
Albumin, g/L (SD) 34.1 (6.0) 33.0 (5.8) 32.4 (5.4) 1/5/4
Creatinine, umol/L (SD) 73.7 (37.0) 70.5 (23.8) 77.4 (26.1) 1/0/0
Phosphate, mmol/L (SD) 0.94 (0.27) 0.86 (0.22) 0.97 (0.24) 1/0/0
Alkaline phosphatase, U/L (SD) 98.6 (37.8) 78.7 (26.2) 79.4 (51.1) 1/0/0
Parathyroid Hormone (PTH), pmol/L (SD) 4.20 (2.12) 5.35 (3.01) 5.10 (3.91) 1/0/0
*Significant difference between groups, p <0.05.
†Refers to loading dose of vitamin D2 at baseline; all groups received 1,000 IU vitamin D3 /daily following loading dose.
Values are the mean (SD), or number (%)
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cant increase in 25-OHD levels for all three groups, 1 in
4 participants in the placebo and 50,000 groups and 1 in
2 participants in the 100,000 group did not achieve the
target therapeutic level (≥75 nmol/L) by 3-months.
While not significantly different from the other two
groups, the low number of participants in the 100,000
groups that did achieve the therapeutic level is an inter-
esting finding and needs further investigation. Our find-
ings suggest that daily 1,000 IU vitamin D3 may be
nearly as or equally effective as providing an additional
large loading dose of vitamin D2 for improving vitamin
D levels in hip fracture patients, but many patients may
still not achieve the therapeutic target. A daily dose of
Figure 2 Distribution of serum 25-OHD values by treatment group at Week 4 and 3 months.
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group of patients.
Daily vitamin D administration is at least as effective
at elevating serum 25-OHD levels as compared with
higher doses of vitamin D administered less frequently.
In one study [22], after 8-weeks, no significant differ-
ences were found in serum 25-OHD levels for daily
(1,500 IU vitamin D3), weekly (10,500 IU vitamin D3)o r
monthly (45,000 IU vitamin D3) dosing in 48 hip frac-
ture patients. In addition, other investigators have
demonstrated that a high does regimen of cholecalci-
ferol 50, 000 IU daily for 10 days versus continuous
low-dose cholecalciferol regimen of 3000 IU daily for 30
days, followed by 1000 IU daily for 60 days were both
effective in increasing serum 25-OHD levels [30]. In a
study of 40 elderly women, Pekkarinin et al. [20] found
that daily 800 IU vitamin D3 w a sm o r ee f f e c t i v ei n
increasing serum 25-OHD levels than 97,333 IU vitamin
D3 every four months (treatment groups were equivalent
in terms of cumulative annual dose). In a cohort of
elderly women with hip fractures, a group taking oral
800 IU vitamin D3 daily had similar 25-OHD after 12-
months as a group taking a single injection of 300,000
IU of vitamin D2 (50 vs. 40 nmol/L) [31]. In a 4-month
study of 338 elderly nursing home residents [23], daily
600 IU vitamin D3 was more effective than weekly 4200
IU vitamin D3 or monthly 18,000 IU vitamin D3 doses.
While others investigators have found that daily
regimens are at least as effective as monthly or weekly
regimens assuming the same cumulative dose, our study
is the first to show that providing a one time, large dose
of vitamin D2 prior to daily vitamin D3 supplementation
was not advantageous with respect to achieving optimal
25-OHD levels after several weeks.
In a sub-group of patients who were tested 1-3 days
after receiving either the placebo or loading dose, an
almost immediate rise in 25-OHD was observed in the
loading dose groups compared with placebo, which was
statistically significant for the 100,000 group. Other stu-
dies have seen similar initial increases in 25-OHD after
large doses of vitamin D3 [45,000 IU [22]; 300,000 IU
[32]] and vitamin D2 [300,000 IU [32]]. In a study with
frail elderly patients, a loading dose of 500,000 IU vita-
min D3 (without daily maintenance therapy) resulted in
a rapid increase in 25-OHD in the first month, but pro-
gressively decreased reaching a mean of 59 nmol/L by
9-months [24]. In our study we found no significant dif-
ferences in 25-OHD levels between groups after 4 weeks
or 3 months after the placebo/vitamin D2 loading. It is
possible that a large loading dose may not be as effective
for long-term maintenance of optimal vitamin D levels
because the large dose may induce increased 24-hydro-
xylase, causing an increased catabolism of both 25-OHD
and 1,25-(OH)2 vitamin D. Therefore, less substrate is
available for the production of 1,25-(OH)2 vitamin D,
the biologically active form of vitamin D, and when
Table 2 Mean (95% CI) 25-OHD and percent reaching 75 nmol/L (N = 65)
Placebo 50,000 100,000 p-value
Baseline (n = 59)
Mean 25-OHD, unadjusted
serum collection at -3 to 0 days, n = 34 58.7 (43.4-74.0)
n=7
52.3 (37.4-67.2)
n=1 4
44.3 (30.8-57.8)
n=1 3
0.39
serum collection at days 1-3, n = 25 41.6 (29.3-53.9)
n=1 1
59.0 (28.4-89.6)
n=6
76.0 (49.1-102.8)
n=8
0.03
†
Mean 25-OHD, adjusted for time to measure, n = 59
‡ 46.7 (34.8-58.6)
n = 18)
53.5 (42.3-64.8)
n=2 0
58.4 (47.3-69.5)
n=2 1
0.37
4-week (n = 50)
Mean 25-OHD, unadjusted 69.8 (59.8-79.8)
n=1 7
84.1 (69.3-98.9)
n=1 7
75.6 (67.6-83.6)
n=1 6
0.17
Mean 25-OHD, adjusted for time to measure* 69.3 (58.4-80.2)
n=1 7
84.5 (73.7-95.3)
n=1 7
75.6 (64.5-86.8)
n=1 6
0.15
Proportion ≥ 75 nmol/L 47.1% 58.8% 50.0% 0.76
3-month (n = 47)
Unadjusted 85.0 (73.6-93.3)
n=1 7
85.2 (74.5-95.9)
n=1 2
74.3 (66.1-82.5)
n=1 8
0.17
Mean 25-OHD, adjusted for time to measure** 86.7 (77.6-95.9)
n=1 7
84.2 (73.6-94.9)
n=1 2
73.3 (64.5-82.1)
n=1 8
0.09
Proportion ≥ 75 nmol/L 76.5% 75% 44.4% 0.09
Baseline data (n = 59) was missing for two participants, and four outliers with 25-OHD taken at 6, 10 or 12 days were not included. 4-week data (n = 50) was
missing for 13 participants, and two outliers with 25-OHD taken at <13 days were not included. 3-month data (n = 47) was missing for 18 participants.
†Significant difference between 100,000 and placebo (post-hoc).
‡Mean time between bolus vitamin D dose and baseline 25-OHD measure was 0.36 days. *Mean
time between bolus vitamin D dose and 25-OHD at second measure was 28.1 days. **Mean time between bolus vitamin D dose and 25-OHD at third measure
was 98.9 days.
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gests that a regimen of 1,000 IU vitamin D daily is as
effective as vitamin D daily plus one loading dose, but
further research is required to confirm whether the
loading dose provides a benefit prior to the 4-week time
point.
Our study demonstrated low 25-OHD levels in hip
fracture patients. In addition, other investigators have
found even lower serum levels, which highlights the
need for vitamin D supplementations [33]. A key finding
in the current study was that many patients had not
achieved the therapeutic target of 75 nmol/L at the 3-
month time-point. Previous studies comparing daily to
weekly or monthly regimens have also reported sub-
optimal vitamin D levels at the end of the study despite
supplementation. In a cohort similar to ours, Ish-Shalom
et al. [22] found that only half of patients with initial 25-
OHD nmol/L below 50 nmol/L, and 80% of those with
25-OHD 50 nmol/L and above, achieved the therapeutic
target (75 nmol/L) after 8-weeks of 1500 IU vitamin D3
daily. In nursing homes residents receiving 600 IU vita-
min D3 daily, fewer than 40% achieved vitamin D levels
of 75 nmol/L after 4 months [23]. Among elderly
women with hip fractures receiving either 800 IU vita-
min D3 daily or 97,333 IU monthly, 47% of the daily
group and 28% of the monthly group achieved 75 nmol/
L after 12 months [20]. Therefore other strategies such
as a higher daily dose may need to be considered to
enable a greater proportion of hip fracture patients to
achieve optimal 25-OHD levels.
Achieving adequate 25-OHD levels after hip fracture
is important from a therapeutic standpoint and may be
needed to ensure optimal effectiveness of bisphospho-
nates [13,14]. In meta-analyses, a minimum daily dose
of daily 700 IU vitamin D3 was considered necessary to
prevent falls and osteoporotic fractures [34-36].
A number of limitations are acknowledged here.
Although, we randomized patients into study groups, we
found a significant difference in age among groups. Due
to our sample size, and because some patients did not
have a baseline measure pri o rt ot h eb o l u sd o s e ,w e
were unable to properly examine patients with greater
baseline vitamin D deficiency or insufficiency. We did
not examine the seasonal influence on 25-OHD levels
since this was a short-term study and the majority of
our patients were hospitalized for approximately a third
or more of the study period. However, our results are
consistent with other studies which have found that
high dose vitamin D3 is not more effective than daily
dosing [20,22,23]. D3 was not used as a loading dose
because it is not available in Canada. Further research
will need to be conducted to determine if a loading dose
of D3 plus daily vitamin D3 is more effective as com-
pared with a loading dose of D2 and to determine the
most effective daily dose. In addition, parathyroid hor-
mone levels were not measured so the relationship
between the hormone and vitamin D levels could not be
described. Examining the efficacy of vitamin D supple-
mentation for the prevention of falls in the first 3-
months post-hip fracture would be interesting given
recent reports regarding the need for 25-OHD levels to
be at 60 nmol/L for optimal fall prevention [37] and the
recent observation that a single, once yearly, very large
dose of vitamin D3 (500,000 IU) is associated with an
increased risk of fall or fracture [38].
Conclusions
Our findings reveal that a simple daily 1,000 IU vitamin
D3 dosing regimen may be as effective as a regimen that
adds a loading dose of vitamin D2 to daily vitamin D3
for increasing 25-OHD levels as early as 4-weeks. How-
ever, more than 25% of all study patients taking 1,000
IU vitamin D3 (with or without the loading dose) still
did not achieve the target 25-OHD level of at least 75
nmol/L. Future studies should examine higher daily
doses of vitamin D3 (i.e. 2,000 IU) as well as the benefits
of an additional loading dose in patients who are
severely deficient.
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